Celltrion, Inc. (068270.KS)
KRW 193100.0
(-3.06%)
KRW 193100.0
(-3.06%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1010.9 Billion KRW | -2.11% |
| 2022 | 1032.69 Billion KRW | -6.61% |
| 2021 | 1105.79 Billion KRW | 7.6% |
| 2020 | 1027.66 Billion KRW | 62.22% |
| 2019 | 633.49 Billion KRW | 14.99% |
| 2018 | 550.9 Billion KRW | -21.05% |
| 2017 | 697.83 Billion KRW | 75.95% |
| 2016 | 396.6 Billion KRW | 7.53% |
| 2015 | 368.84 Billion KRW | 8.12% |
| 2014 | 341.13 Billion KRW | 116.56% |
| 2013 | 157.52 Billion KRW | -38.54% |
| 2012 | 256.28 Billion KRW | 13.01% |
| 2011 | 226.78 Billion KRW | 60.25% |
| 2010 | 141.51 Billion KRW | 50.62% |
| 2009 | 93.95 Billion KRW | 97.59% |
| 2008 | 47.55 Billion KRW | 415.47% |
| 2007 | 9.22 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 294.25 Billion KRW | 57.65% |
| 2024 Q1 | 233.32 Billion KRW | 72.23% |
| 2023 FY | 1010.9 Billion KRW | -2.11% |
| 2023 Q4 | 135.47 Billion KRW | -63.42% |
| 2023 Q1 | 264.17 Billion KRW | 32.11% |
| 2023 Q3 | 370.34 Billion KRW | 34.1% |
| 2023 Q2 | 276.17 Billion KRW | 4.54% |
| 2022 Q4 | 199.96 Billion KRW | -33.34% |
| 2022 Q3 | 299.99 Billion KRW | -0.07% |
| 2022 Q2 | 300.21 Billion KRW | 19.37% |
| 2022 Q1 | 251.49 Billion KRW | -21.77% |
| 2022 FY | 1032.69 Billion KRW | -6.61% |
| 2021 Q3 | 247.83 Billion KRW | 3.54% |
| 2021 Q1 | 297.09 Billion KRW | 5.04% |
| 2021 Q2 | 239.37 Billion KRW | -19.43% |
| 2021 FY | 1105.79 Billion KRW | 7.6% |
| 2021 Q4 | 321.48 Billion KRW | 29.72% |
| 2020 Q4 | 282.83 Billion KRW | -11.55% |
| 2020 FY | 1027.66 Billion KRW | 62.22% |
| 2020 Q1 | 185.36 Billion KRW | -1.81% |
| 2020 Q3 | 319.75 Billion KRW | 33.4% |
| 2020 Q2 | 239.69 Billion KRW | 29.31% |
| 2019 Q1 | 132.96 Billion KRW | 24.97% |
| 2019 FY | 633.49 Billion KRW | 14.99% |
| 2019 Q3 | 170.29 Billion KRW | 20.41% |
| 2019 Q4 | 188.79 Billion KRW | 10.86% |
| 2019 Q2 | 141.43 Billion KRW | 6.37% |
| 2018 Q3 | 127.61 Billion KRW | -18.56% |
| 2018 Q4 | 106.39 Billion KRW | -16.63% |
| 2018 FY | 550.9 Billion KRW | -21.05% |
| 2018 Q1 | 156.1 Billion KRW | -29.11% |
| 2018 Q2 | 156.69 Billion KRW | 0.38% |
| 2017 Q2 | 174.4 Billion KRW | 46.17% |
| 2017 FY | 697.83 Billion KRW | 75.95% |
| 2017 Q4 | 220.22 Billion KRW | 19.76% |
| 2017 Q3 | 183.88 Billion KRW | 5.43% |
| 2017 Q1 | 119.31 Billion KRW | 10.91% |
| 2016 Q4 | 107.58 Billion KRW | -3.31% |
| 2016 Q3 | 111.26 Billion KRW | 0.15% |
| 2016 Q1 | 66.64 Billion KRW | -28.18% |
| 2016 FY | 396.6 Billion KRW | 7.53% |
| 2016 Q2 | 111.1 Billion KRW | 66.71% |
| 2015 Q1 | 62.96 Billion KRW | -10.64% |
| 2015 Q3 | 102.51 Billion KRW | -7.29% |
| 2015 Q4 | 92.78 Billion KRW | -9.49% |
| 2015 Q2 | 110.57 Billion KRW | 75.63% |
| 2015 FY | 368.84 Billion KRW | 8.12% |
| 2014 Q2 | 140.91 Billion KRW | 149.71% |
| 2014 FY | 341.13 Billion KRW | 116.56% |
| 2014 Q4 | 70.45 Billion KRW | -3.93% |
| 2014 Q3 | 73.33 Billion KRW | -47.95% |
| 2014 Q1 | 56.43 Billion KRW | 930.67% |
| 2013 Q3 | 58.85 Billion KRW | 25.77% |
| 2013 FY | 157.52 Billion KRW | -38.54% |
| 2013 Q4 | -6.79 Billion KRW | -111.54% |
| 2013 Q1 | 58.66 Billion KRW | -24.55% |
| 2013 Q2 | 46.79 Billion KRW | -20.23% |
| 2012 FY | 256.28 Billion KRW | 13.01% |
| 2012 Q1 | 58.08 Billion KRW | 0.0% |
| 2012 Q3 | 67.1 Billion KRW | 24.79% |
| 2012 Q4 | 77.75 Billion KRW | 15.86% |
| 2012 Q2 | 53.77 Billion KRW | -7.41% |
| 2011 Q3 | 57.87 Billion KRW | 5.27% |
| 2011 Q2 | 54.97 Billion KRW | 9.43% |
| 2011 Q1 | 50.23 Billion KRW | 33.88% |
| 2011 FY | 226.78 Billion KRW | 60.25% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q2 | 35.93 Billion KRW | 34.77% |
| 2010 Q1 | 26.66 Billion KRW | 18.57% |
| 2010 Q3 | 41.39 Billion KRW | 15.22% |
| 2010 Q4 | 37.52 Billion KRW | -9.36% |
| 2010 FY | 141.51 Billion KRW | 50.62% |
| 2009 Q4 | 22.48 Billion KRW | 5.9% |
| 2009 FY | 93.95 Billion KRW | 97.59% |
| 2009 Q3 | 21.23 Billion KRW | -19.81% |
| 2009 Q2 | 26.47 Billion KRW | 11.42% |
| 2009 Q1 | 23.76 Billion KRW | 172.81% |
| 2008 Q1 | 2.02 Billion KRW | 0.0% |
| 2008 Q3 | 24.6 Billion KRW | 1210.15% |
| 2008 Q4 | 8.71 Billion KRW | -64.6% |
| 2008 FY | 47.55 Billion KRW | 415.47% |
| 2008 Q2 | 1.87 Billion KRW | -7.02% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q2 | 1.77 Billion KRW | -10.05% |
| 2007 Q1 | 1.97 Billion KRW | 0.0% |
| 2007 FY | 9.22 Billion KRW | 0.0% |
| 2007 Q3 | 2.36 Billion KRW | 33.45% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ORIENT BIO Inc. | 9.58 Billion KRW | -10447.374% |
| Green Cross Holdings Corporation | 603.58 Billion KRW | -67.484% |
| Green Cross Holdings Corporation | 458.68 Billion KRW | -120.39% |
| Pharmicell Co., Ltd. | 14.95 Billion KRW | -6659.546% |
| Green Cross Corporation | 458.68 Billion KRW | -120.39% |
| GeneOne Life Science, Inc. | -14.98 Billion KRW | 6846.41% |
| Samsung Biologics Co.,Ltd. | 1802.76 Billion KRW | 43.925% |
| SK bioscience Co.,Ltd. | 142.24 Billion KRW | -610.688% |
| SK Biopharmaceuticals Co., Ltd. | 308.37 Billion KRW | -227.817% |
| Prestige BioPharma Limited | 689.07 Million KRW | -146604.319% |